FemHealth Ventures’ Post

“We have nowhere near the capacity to manage all those patients” New research from the US shows that specialists would struggle to cope with the high number of patients with steatotic liver disease. This is largely due to 90% of these patients being overweight, and about 50% of those requiring disease management. In an ideal world, we'd have a system that could detect and manage all these patients, but economic challenges stand in the way. That's where Fatty Liver Alliance and Geoff Red (MSOD) are spot on. At Evido, we are addressing this challenge with a core focus on the entire patient journey and ensuring a sustainable patient pathway from primary care to specialist care. We are dedicated to enabling efficient and affordable detection and management of these people – thereby bridging the gap between the ideal and the real world. 🚀 #datadrivendiagnostics #healthtech #liverdiagnostics

We were excited this summer when Zurzuvae, the first oral treatment for postpartum depression, was approved by the FDA. Postpartum depression affects as many as 1 in 8 people who have babies, according to the CDC. And this drug, from Sage and Biogen, was shown to improve depressive symptoms in as little as three days. The companies’ goal was “to enable broad and equitable access for women with PPD who are prescribed this drug.” Yet the announcement this week of a price of $15,900 for a 14-day course raises real concerns about equity and whether this drug will actually be accessible to those that need it. We now put this in the hands of insurance companies with the hope they will cover it in a meaningful way. And, that they don’t require women to “fail” treatment with less-expensive options before paying for this drug. Let’s hope they get this one right. https://lnkd.in/gW6KFi3S #womenshealth #maternalhealth #maternalmentalhealth

Today, on World Kidney Day, we at Indian Society for Clinical Research join the global community in focusing on the vital importance of kidney health. This year's theme, "Kidney Health for Everyone Everywhere," emphasises the need for universal access to kidney care and the critical role that clinical trials play in achieving this goal. In light of this, we wish to highlight an insightful piece from the American Kidney Fund that delves into the pivotal role of clinical trials for kidney disease, offering a deep dive into how these research endeavours lead to significant advancements in treatment and patient care. As we commemorate this day, let's renew our pledge to push the boundaries of what's possible through clinical research and innovation. Together, we can achieve remarkable strides in kidney health, ensuring that effective treatments are within reach for everyone, everywhere. Discover more about the transformative impact of clinical trials on kidney health here: https://lnkd.in/dqiqUuwS Indian Society of Nephrology Dr. Sanish Davis MD, DM,FCP Dr.Seema Pai Anirban Roy Chowdhury Dr. Chirag Trivedi SUNEELA THATTE Gaurav Mathur Ph.D, MBA Kedar Nayak Mala Srivastava MRQA Anushila Vaishali Gaurab C. Sachin Tonapi CCDM® Thanuja Naidu #WorldKidneyDay #FutureofClinicalResearch #KidneyHealth #Health #KidneyTreatment #Medical #ISCR #ClinicalResearch #HealthcareInnovation #ISCR2024 #MedicalScience #IndianScience #ClinicalTrials #HealthTech #MedicalResearch #BetterOutcomes #UniversalAccess

A possible relative contraindication to using Diltiazem doses in excess of 120mg with Apixaban and Rivaroxaban. In this retrospective cohort study comparing Diltiazem and Metoprolol for rate control in Atrial Fibrillation, involving 204155 patients, 1 year follow up and Medicare beneficiaries aged 65 and older. A Hazard ratio of 1.22 was found for bleeding related hospitalization, Diltiazem relative to Metoprolol. The mechanism of interaction being that of CYP3A4 inhibition increasing AUC for Apixaban by upto 40%. A follow up question worthy of investigation is whether a reduced dose of Apixaban or Rivaroxaban should be considered in patients requiring more that 120mg of Diltiazem in patients who cannot receive beta blockers.

It's a wet and dreary day here in Dublin ☔ But, the team at HealthBeacon is beaming with excitement to announce that our Pathfinder Risk Management Platform (RMP) has been shortlisted in the Health Service Journal Patient Safety Awards 2023 🎉 The platform was nominated in the following categories: - Improving Medicines Safety - Safety Improvement Through Technology. The platform was used as part of an innovative digital pregnancy prevention plan for lenalidomide, an anti-cancer medicine used to treat myeloma, some types of lymphoma and myelodysplastic syndromes in c. 10,000 patients in the UK. This drug although life-changing for many patients, is structurally related to thalidomide, a known teratogenic medicine that causes birth defects. Patient safety was at the core of developing this platform and we're particularly proud of what our team has achieved and the impact it's had on patients' lives 💚 As always, this came to fruition as a result of the incredible partnerships between NHS England, NHS National Services Scotland Medicines and Healthcare products Regulatory Agency, British Generic Manufacturers Association (BGMA) and PharmaCare Group who all worked closely with patients and patient groups to bring this platform to life. As of July 2023: -      95% of trusts/health boards across the UK have now registered -      2,500 healthcare professionals using the system -      More than 26,000 patient Prescription Authorisation Forms processed We are a very proud HealthBeacon team today 😁 #lenalidomide #HSJPatientSafetyAwards #patientsafety #NHSEngland #NHSScotland #GIGCymru #NHSWales #NWSSP #goteamgo #patientfirst

🌟 OTAG and CMS Updates 🌟 The Organ Transplantation Affinity Group (OTAG) plays a vital role in strengthening accountability, equity, and performance in organ transplantation. Recent changes from the Centers for Medicare & Medicaid Services (CMS) underscore the need for heightened awareness. 🤝 Our Commitment to You 🤝 We are dedicated to keeping our clients in the loop about these crucial developments. Our team is always on the forefront, ensuring that you receive the most up-to-date information on compliance, policy changes, and best practices. 💡 Why It Matters 💡 Staying current with CMS standards and HRSA initiatives is essential to providing the best care possible. We're here to help you navigate these changes seamlessly, ensuring that you maintain the highest standards of care and compliance. 📚 Knowledge is Power 📚 Count on Dominant Compliance to be your partner in excellence. We're committed to your success and the well-being of your patients. #HealthcareUpdates #OTAG #CMSChanges #ComplianceMatters #DominantCompliance

🌟 OTAG and CMS Updates 🌟 The Organ Transplantation Affinity Group (OTAG) plays a vital role in strengthening accountability, equity, and performance in organ transplantation. Recent changes from the Centers for Medicare & Medicaid Services (CMS) underscore the need for heightened awareness. 🤝 Our Commitment to You 🤝 We are dedicated to keeping our clients in the loop about these crucial developments. Our team is always on the forefront, ensuring that you receive the most up-to-date information on compliance, policy changes, and best practices. 💡 Why It Matters 💡 Staying current with CMS standards and HRSA initiatives is essential to providing the best care possible. We're here to help you navigate these changes seamlessly, ensuring that you maintain the highest standards of care and compliance. 📚 Knowledge is Power 📚 Count on Dominant Compliance to be your partner in excellence. We're committed to your success and the well-being of your patients. #HealthcareUpdates #OTAG #CMSChanges #ComplianceMatters #DominantCompliance

We love to collaborate with others to ensure you have your #GIDreamTeam. The research around the importance of a multidisciplinary integrated treatment approach is increasing as we continue to see the benefits of collaborating around client care from different perspectives. Check out this article highlighting the benefits of treatment amongst #FGID patients in a structured multidisciplinary care setting - https://loom.ly/q6fjaqE #GIPsych #GIPsychology #mindyourgut #DGBIs #emotionalwellbeing #careteam

Learn more about the first and only FDA-cleared biomarkers for the risk assessment and clinical management of #preeclampsia with severe features. Contact us today. #MaternalHealth #thermofisheremp #thermofisheremp

Learn more about the first and only FDA-cleared biomarkers for the risk assessment and clinical management of #preeclampsia with severe features. Contact us today. #MaternalHealth #thermofisheremp #thermofisheremp